Verona Pharma sees Q4 net product sales revenue $36M vs. $0M a year ago

Consensus for Q4 revenue is $12.94M. Expects to report cash and cash equivalents at December 31, 2024, of $400M vs. $271.8M a year ago. “2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”),” said CEO David Zaccardelli. “We are very pleased to report the exceptionally strong start to the launch of Ohtuvayre continues with more than 3,500 unique healthcare professionals prescribing Ohtuvayre and over 16,000 prescriptions filled of which approximately one-third were patient refills in 2024…Specifically, filled prescriptions increased by over 35% each month in Q4 and physicians continued to prescribe Ohtuvayre across a broad COPD population including those receiving background single, dual and triple therapy. We recorded net product sales of approximately $36M in Q4 and $42M for full year 2024…We are excited by the initial impact of Ohtuvayre and look forward to building on this momentum in 2025.”